Among elevated risk adults having type 2 diabetes, scientists have observed that duo therapies could slacken the advancement of diabetic retinopathy, an eye condition which is the key reason for eyesight failure among people of working age in the United States.
Rigorous blood glucose control lowered the advancement of diabetic retinopathy in comparison to the benchmark blood glucose control and combining lipid treatment alongside ‘statin + fibrate’ additionally lowered the condition advancement in comparison with stand-alone statin treatment. But, rigorous blood pressure management offered zilch added advantage to such people in comparison with the benchmark blood pressure control.
The NIH backed ACCORD eye study lucidly suggests that rigorous glycemic control plus fibrate therapy combined with statin treatment independently reduced the advancement of diabetic retinopathy. The chief ACCORD (Action to Control Cardiovascular Risk in Diabetes) eye study outcomes indicate that fibrate therapy included along with statin treatment could be safely given to patients. But, rigorous blood glucose management to close-to-normal levels augmented the chances of fatality and acute dip in blood glucose hence the patient as well as physician need to take such likely risks into consideration during implementation of a diabetes therapy plan.
The ACCORD trial was a milestone scientific study which entailed 10251 adults having type 2 diabetes and had a particularly elevated risk of suffering from strokes, heart attacks or its associated fatality. The trial assessed 3 rigorous approaches contrasted against benchmark therapies for reducing heart disease risks linked to diabetes.
Exhaustive therapies comprised of controlling blood pressure and blood glucose levels to normal range and merging therapy of multiple blood lipids alongside simvastatin+fenofibrate in comparison to benchmark therapy involving just simvastatin.
Febofibrate therapy reduces triglyceride levels and increases the levels of HDL (good cholesterol). Simvastatin reduces the levels of LDL (bad cholesterol). The study entrants were registered for the blood glucose study and in the lipid or blood pressure study.
The ACCORD Eye Study entailed a subgroup of 2856 entrants. Investigators evaluated the outcomes of the therapy approaches on eye blood vessels by detecting diabetic retinopathy advancement over a 4-year period.
Diabetic retinopathy is a condition wherein the photosensitive retinal tissue blood vessels are harmed as a result of diabetes. As a result, there is leakage in these blood vessels, leading to retinal swell up and irregular novel blood vessel development which lead to eyesight failure.
During the trial, advancement of the condition was spotted via images of the retina which suggested blood vessel alterations or by the requirement of laser surgery or eye surgery for treating abnormally formed vessels.
In comparison to benchmark blood glucose regulation, thorough control lessened advancement of the disease by nearly 1/3rd over a 4-year period.
Although earlier scientific studies have exhibited the advantageous outcomes of rigorous blood glucose control on slackening the advancement of diabetic retinopathy, the ACCORD Eye Study is claimed to expand such discoveries to a bigger populace of type 2 diabetes cases for an average of a decade and illustrates that the eye advantages from reducing blood sugar below earlier set levels.
Additionally, in comparison to stand-alone simvastatin therapy, merged lipid treatment along with simvastin + fenofibrate additionally lowered disease advancement by around 1/3rd over 4 years.
No variation in disease advancement was observed amongst study entrants undergoing treatment to a rigorous systolic BP aim of < 120mm Hg in comparison to those people undergoing treatment to a benchmark goal of < 140 mm Hg.
